nodes	percent_of_prediction	percent_of_DWPC	metapath
Apomorphine—CALY—testis—hematologic cancer	0.00129	0.12	CbGeAlD
Apomorphine—DRD5—hematopoietic system—hematologic cancer	0.00119	0.111	CbGeAlD
Apomorphine—DRD4—testis—hematologic cancer	0.00099	0.0922	CbGeAlD
Apomorphine—CALY—lymph node—hematologic cancer	0.000934	0.087	CbGeAlD
Apomorphine—HTR1A—hematopoietic system—hematologic cancer	0.000594	0.0554	CbGeAlD
Apomorphine—HTR2B—blood—hematologic cancer	0.000439	0.0409	CbGeAlD
Apomorphine—ADRA2A—hematopoietic system—hematologic cancer	0.000417	0.0388	CbGeAlD
Apomorphine—HTR2B—lung—hematologic cancer	0.000385	0.0359	CbGeAlD
Apomorphine—HTR2A—hematopoietic system—hematologic cancer	0.000354	0.033	CbGeAlD
Apomorphine—ADRA2C—blood—hematologic cancer	0.000346	0.0322	CbGeAlD
Apomorphine—Dyspnoea—Cisplatin—hematologic cancer	0.000321	0.000487	CcSEcCtD
Apomorphine—Shock—Prednisolone—hematologic cancer	0.00032	0.000486	CcSEcCtD
Apomorphine—Hyperhidrosis—Etoposide—hematologic cancer	0.000319	0.000484	CcSEcCtD
Apomorphine—Asthenia—Thalidomide—hematologic cancer	0.000319	0.000484	CcSEcCtD
Apomorphine—Feeling abnormal—Gemcitabine—hematologic cancer	0.000318	0.000483	CcSEcCtD
Apomorphine—Dizziness—Vinorelbine—hematologic cancer	0.000318	0.000483	CcSEcCtD
Apomorphine—Orthostatic hypotension—Doxorubicin—hematologic cancer	0.000318	0.000482	CcSEcCtD
Apomorphine—Nausea—Lenalidomide—hematologic cancer	0.000318	0.000482	CcSEcCtD
Apomorphine—Angina pectoris—Epirubicin—hematologic cancer	0.000317	0.000481	CcSEcCtD
Apomorphine—ADRA2A—gonad—hematologic cancer	0.000317	0.0295	CbGeAlD
Apomorphine—Hyperhidrosis—Prednisolone—hematologic cancer	0.000315	0.000477	CcSEcCtD
Apomorphine—Pruritus—Thalidomide—hematologic cancer	0.000314	0.000477	CcSEcCtD
Apomorphine—Diarrhoea—Thiotepa—hematologic cancer	0.000314	0.000477	CcSEcCtD
Apomorphine—Nausea—Hydroxyurea—hematologic cancer	0.000314	0.000476	CcSEcCtD
Apomorphine—Vomiting—Bortezomib—hematologic cancer	0.000313	0.000475	CcSEcCtD
Apomorphine—DRD2—lung—hematologic cancer	0.000312	0.029	CbGeAlD
Apomorphine—Pneumonia—Methotrexate—hematologic cancer	0.000312	0.000473	CcSEcCtD
Apomorphine—Nasopharyngitis—Doxorubicin—hematologic cancer	0.000311	0.000472	CcSEcCtD
Apomorphine—Vomiting—Bleomycin—hematologic cancer	0.000311	0.000472	CcSEcCtD
Apomorphine—Drowsiness—Methotrexate—hematologic cancer	0.00031	0.00047	CcSEcCtD
Apomorphine—Flushing—Prednisone—hematologic cancer	0.000309	0.000469	CcSEcCtD
Apomorphine—Headache—Bortezomib—hematologic cancer	0.000309	0.000468	CcSEcCtD
Apomorphine—Hypotension—Etoposide—hematologic cancer	0.000308	0.000468	CcSEcCtD
Apomorphine—Asthenia—Carmustine—hematologic cancer	0.000306	0.000464	CcSEcCtD
Apomorphine—Vomiting—Vinorelbine—hematologic cancer	0.000306	0.000464	CcSEcCtD
Apomorphine—Diarrhoea—Thalidomide—hematologic cancer	0.000304	0.000461	CcSEcCtD
Apomorphine—Dizziness—Thiotepa—hematologic cancer	0.000304	0.000461	CcSEcCtD
Apomorphine—Asthenia—Alitretinoin—hematologic cancer	0.000303	0.00046	CcSEcCtD
Apomorphine—ADRA2C—lung—hematologic cancer	0.000303	0.0282	CbGeAlD
Apomorphine—Headache—Vinorelbine—hematologic cancer	0.000301	0.000457	CcSEcCtD
Apomorphine—Asthenia—Ifosfamide—hematologic cancer	0.0003	0.000455	CcSEcCtD
Apomorphine—Oedema—Triamcinolone—hematologic cancer	0.000299	0.000454	CcSEcCtD
Apomorphine—Pruritus—Alitretinoin—hematologic cancer	0.000299	0.000454	CcSEcCtD
Apomorphine—Syncope—Betamethasone—hematologic cancer	0.000298	0.000453	CcSEcCtD
Apomorphine—Syncope—Dexamethasone—hematologic cancer	0.000298	0.000453	CcSEcCtD
Apomorphine—Feeling abnormal—Cisplatin—hematologic cancer	0.000297	0.00045	CcSEcCtD
Apomorphine—Pruritus—Ifosfamide—hematologic cancer	0.000296	0.000448	CcSEcCtD
Apomorphine—Shock—Triamcinolone—hematologic cancer	0.000294	0.000447	CcSEcCtD
Apomorphine—Insomnia—Prednisolone—hematologic cancer	0.000294	0.000447	CcSEcCtD
Apomorphine—DRD2—testis—hematologic cancer	0.000294	0.0274	CbGeAlD
Apomorphine—Dyspnoea—Etoposide—hematologic cancer	0.000294	0.000446	CcSEcCtD
Apomorphine—Dizziness—Thalidomide—hematologic cancer	0.000294	0.000446	CcSEcCtD
Apomorphine—Somnolence—Etoposide—hematologic cancer	0.000293	0.000445	CcSEcCtD
Apomorphine—Angina pectoris—Doxorubicin—hematologic cancer	0.000293	0.000445	CcSEcCtD
Apomorphine—Nausea—Bortezomib—hematologic cancer	0.000293	0.000444	CcSEcCtD
Apomorphine—Loss of consciousness—Dexamethasone—hematologic cancer	0.000292	0.000444	CcSEcCtD
Apomorphine—Loss of consciousness—Betamethasone—hematologic cancer	0.000292	0.000444	CcSEcCtD
Apomorphine—Asthenia—Vincristine—hematologic cancer	0.000292	0.000443	CcSEcCtD
Apomorphine—Vomiting—Thiotepa—hematologic cancer	0.000292	0.000443	CcSEcCtD
Apomorphine—Diarrhoea—Carmustine—hematologic cancer	0.000292	0.000443	CcSEcCtD
Apomorphine—Pneumonia—Epirubicin—hematologic cancer	0.000292	0.000443	CcSEcCtD
Apomorphine—Mental disorder—Prednisone—hematologic cancer	0.000292	0.000442	CcSEcCtD
Apomorphine—Nausea—Bleomycin—hematologic cancer	0.00029	0.000441	CcSEcCtD
Apomorphine—Drowsiness—Epirubicin—hematologic cancer	0.00029	0.00044	CcSEcCtD
Apomorphine—Hyperhidrosis—Triamcinolone—hematologic cancer	0.000289	0.000439	CcSEcCtD
Apomorphine—Diarrhoea—Alitretinoin—hematologic cancer	0.000289	0.000439	CcSEcCtD
Apomorphine—Headache—Thiotepa—hematologic cancer	0.000288	0.000437	CcSEcCtD
Apomorphine—ADRA2C—testis—hematologic cancer	0.000286	0.0266	CbGeAlD
Apomorphine—Diarrhoea—Ifosfamide—hematologic cancer	0.000286	0.000434	CcSEcCtD
Apomorphine—Nausea—Vinorelbine—hematologic cancer	0.000286	0.000433	CcSEcCtD
Apomorphine—Asthenia—Mitoxantrone—hematologic cancer	0.000285	0.000432	CcSEcCtD
Apomorphine—Asthenia—Irinotecan—hematologic cancer	0.000285	0.000432	CcSEcCtD
Apomorphine—Fatigue—Etoposide—hematologic cancer	0.000284	0.000432	CcSEcCtD
Apomorphine—Vomiting—Thalidomide—hematologic cancer	0.000282	0.000429	CcSEcCtD
Apomorphine—Anxiety—Dexamethasone—hematologic cancer	0.000282	0.000428	CcSEcCtD
Apomorphine—Anxiety—Betamethasone—hematologic cancer	0.000282	0.000428	CcSEcCtD
Apomorphine—Dizziness—Carmustine—hematologic cancer	0.000282	0.000428	CcSEcCtD
Apomorphine—Constipation—Etoposide—hematologic cancer	0.000282	0.000428	CcSEcCtD
Apomorphine—Urinary tract infection—Epirubicin—hematologic cancer	0.000282	0.000428	CcSEcCtD
Apomorphine—Dizziness—Alitretinoin—hematologic cancer	0.00028	0.000424	CcSEcCtD
Apomorphine—Diarrhoea—Vincristine—hematologic cancer	0.000279	0.000423	CcSEcCtD
Apomorphine—Headache—Thalidomide—hematologic cancer	0.000278	0.000422	CcSEcCtD
Apomorphine—Asthenia—Gemcitabine—hematologic cancer	0.000277	0.000421	CcSEcCtD
Apomorphine—Dizziness—Ifosfamide—hematologic cancer	0.000276	0.000419	CcSEcCtD
Apomorphine—ADRA2A—blood—hematologic cancer	0.000276	0.0257	CbGeAlD
Apomorphine—Pruritus—Gemcitabine—hematologic cancer	0.000273	0.000415	CcSEcCtD
Apomorphine—Nausea—Thiotepa—hematologic cancer	0.000273	0.000414	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	0.000273	0.000414	CcSEcCtD
Apomorphine—Feeling abnormal—Etoposide—hematologic cancer	0.000272	0.000413	CcSEcCtD
Apomorphine—Oedema—Dexamethasone—hematologic cancer	0.000272	0.000412	CcSEcCtD
Apomorphine—Oedema—Betamethasone—hematologic cancer	0.000272	0.000412	CcSEcCtD
Apomorphine—Diarrhoea—Irinotecan—hematologic cancer	0.000271	0.000412	CcSEcCtD
Apomorphine—Diarrhoea—Mitoxantrone—hematologic cancer	0.000271	0.000412	CcSEcCtD
Apomorphine—Vomiting—Carmustine—hematologic cancer	0.000271	0.000412	CcSEcCtD
Apomorphine—Insomnia—Triamcinolone—hematologic cancer	0.000271	0.000411	CcSEcCtD
Apomorphine—Pneumonia—Doxorubicin—hematologic cancer	0.00027	0.000409	CcSEcCtD
Apomorphine—Dizziness—Vincristine—hematologic cancer	0.000269	0.000409	CcSEcCtD
Apomorphine—HTR2A—gonad—hematologic cancer	0.000269	0.0251	CbGeAlD
Apomorphine—Vomiting—Alitretinoin—hematologic cancer	0.000269	0.000408	CcSEcCtD
Apomorphine—Drowsiness—Doxorubicin—hematologic cancer	0.000268	0.000407	CcSEcCtD
Apomorphine—Feeling abnormal—Prednisolone—hematologic cancer	0.000268	0.000407	CcSEcCtD
Apomorphine—Headache—Carmustine—hematologic cancer	0.000267	0.000406	CcSEcCtD
Apomorphine—Shock—Dexamethasone—hematologic cancer	0.000267	0.000405	CcSEcCtD
Apomorphine—Shock—Betamethasone—hematologic cancer	0.000267	0.000405	CcSEcCtD
Apomorphine—Dyspnoea—Triamcinolone—hematologic cancer	0.000267	0.000405	CcSEcCtD
Apomorphine—Vomiting—Ifosfamide—hematologic cancer	0.000266	0.000403	CcSEcCtD
Apomorphine—Headache—Alitretinoin—hematologic cancer	0.000265	0.000402	CcSEcCtD
Apomorphine—Diarrhoea—Gemcitabine—hematologic cancer	0.000264	0.000401	CcSEcCtD
Apomorphine—Nausea—Thalidomide—hematologic cancer	0.000264	0.0004	CcSEcCtD
Apomorphine—HTR2B—lymph node—hematologic cancer	0.000264	0.0245	CbGeAlD
Apomorphine—Hyperhidrosis—Dexamethasone—hematologic cancer	0.000263	0.000398	CcSEcCtD
Apomorphine—Hyperhidrosis—Betamethasone—hematologic cancer	0.000263	0.000398	CcSEcCtD
Apomorphine—Dizziness—Irinotecan—hematologic cancer	0.000262	0.000398	CcSEcCtD
Apomorphine—Urinary tract infection—Doxorubicin—hematologic cancer	0.000261	0.000396	CcSEcCtD
Apomorphine—Syncope—Prednisone—hematologic cancer	0.00026	0.000394	CcSEcCtD
Apomorphine—Vomiting—Vincristine—hematologic cancer	0.000259	0.000393	CcSEcCtD
Apomorphine—Asthenia—Cisplatin—hematologic cancer	0.000258	0.000392	CcSEcCtD
Apomorphine—Fatigue—Triamcinolone—hematologic cancer	0.000258	0.000391	CcSEcCtD
Apomorphine—Headache—Vincristine—hematologic cancer	0.000255	0.000387	CcSEcCtD
Apomorphine—Loss of consciousness—Prednisone—hematologic cancer	0.000255	0.000386	CcSEcCtD
Apomorphine—Hypotension—Dexamethasone—hematologic cancer	0.000254	0.000385	CcSEcCtD
Apomorphine—Hypotension—Betamethasone—hematologic cancer	0.000254	0.000385	CcSEcCtD
Apomorphine—Nausea—Carmustine—hematologic cancer	0.000253	0.000385	CcSEcCtD
Apomorphine—Vomiting—Mitoxantrone—hematologic cancer	0.000252	0.000383	CcSEcCtD
Apomorphine—Vomiting—Irinotecan—hematologic cancer	0.000252	0.000383	CcSEcCtD
Apomorphine—Nausea—Alitretinoin—hematologic cancer	0.000251	0.000381	CcSEcCtD
Apomorphine—Headache—Mitoxantrone—hematologic cancer	0.000249	0.000377	CcSEcCtD
Apomorphine—Headache—Irinotecan—hematologic cancer	0.000249	0.000377	CcSEcCtD
Apomorphine—Nausea—Ifosfamide—hematologic cancer	0.000248	0.000376	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.000247	0.000375	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.000247	0.000375	CcSEcCtD
Apomorphine—Arthralgia—Prednisone—hematologic cancer	0.000247	0.000374	CcSEcCtD
Apomorphine—Feeling abnormal—Triamcinolone—hematologic cancer	0.000247	0.000374	CcSEcCtD
Apomorphine—Diarrhoea—Cisplatin—hematologic cancer	0.000246	0.000374	CcSEcCtD
Apomorphine—Anxiety—Prednisone—hematologic cancer	0.000246	0.000373	CcSEcCtD
Apomorphine—Vomiting—Gemcitabine—hematologic cancer	0.000246	0.000373	CcSEcCtD
Apomorphine—Insomnia—Betamethasone—hematologic cancer	0.000246	0.000373	CcSEcCtD
Apomorphine—Insomnia—Dexamethasone—hematologic cancer	0.000246	0.000373	CcSEcCtD
Apomorphine—Mental disorder—Methotrexate—hematologic cancer	0.000244	0.00037	CcSEcCtD
Apomorphine—Headache—Gemcitabine—hematologic cancer	0.000242	0.000367	CcSEcCtD
Apomorphine—ADRA2A—lung—hematologic cancer	0.000242	0.0225	CbGeAlD
Apomorphine—Nausea—Vincristine—hematologic cancer	0.000242	0.000367	CcSEcCtD
Apomorphine—Flushing—Epirubicin—hematologic cancer	0.000242	0.000367	CcSEcCtD
Apomorphine—Asthenia—Etoposide—hematologic cancer	0.000237	0.000359	CcSEcCtD
Apomorphine—Oedema—Prednisone—hematologic cancer	0.000236	0.000359	CcSEcCtD
Apomorphine—Nausea—Irinotecan—hematologic cancer	0.000236	0.000357	CcSEcCtD
Apomorphine—Nausea—Mitoxantrone—hematologic cancer	0.000236	0.000357	CcSEcCtD
Apomorphine—HTR2A—blood—hematologic cancer	0.000235	0.0219	CbGeAlD
Apomorphine—Back pain—Methotrexate—hematologic cancer	0.000234	0.000355	CcSEcCtD
Apomorphine—Fatigue—Betamethasone—hematologic cancer	0.000234	0.000355	CcSEcCtD
Apomorphine—Fatigue—Dexamethasone—hematologic cancer	0.000234	0.000355	CcSEcCtD
Apomorphine—Pruritus—Etoposide—hematologic cancer	0.000233	0.000354	CcSEcCtD
Apomorphine—Shock—Prednisone—hematologic cancer	0.000233	0.000353	CcSEcCtD
Apomorphine—Nausea—Gemcitabine—hematologic cancer	0.00023	0.000348	CcSEcCtD
Apomorphine—Vomiting—Cisplatin—hematologic cancer	0.000229	0.000347	CcSEcCtD
Apomorphine—Hyperhidrosis—Prednisone—hematologic cancer	0.000229	0.000347	CcSEcCtD
Apomorphine—ADRA2A—testis—hematologic cancer	0.000228	0.0213	CbGeAlD
Apomorphine—Mental disorder—Epirubicin—hematologic cancer	0.000228	0.000346	CcSEcCtD
Apomorphine—Diarrhoea—Etoposide—hematologic cancer	0.000226	0.000343	CcSEcCtD
Apomorphine—Feeling abnormal—Betamethasone—hematologic cancer	0.000224	0.00034	CcSEcCtD
Apomorphine—Feeling abnormal—Dexamethasone—hematologic cancer	0.000224	0.00034	CcSEcCtD
Apomorphine—Flushing—Doxorubicin—hematologic cancer	0.000224	0.000339	CcSEcCtD
Apomorphine—Back pain—Epirubicin—hematologic cancer	0.000219	0.000333	CcSEcCtD
Apomorphine—Dizziness—Etoposide—hematologic cancer	0.000218	0.000331	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.000215	0.000327	CcSEcCtD
Apomorphine—Dizziness—Prednisolone—hematologic cancer	0.000215	0.000327	CcSEcCtD
Apomorphine—Asthenia—Triamcinolone—hematologic cancer	0.000215	0.000326	CcSEcCtD
Apomorphine—Nausea—Cisplatin—hematologic cancer	0.000214	0.000325	CcSEcCtD
Apomorphine—Insomnia—Prednisone—hematologic cancer	0.000214	0.000325	CcSEcCtD
Apomorphine—Pruritus—Triamcinolone—hematologic cancer	0.000212	0.000321	CcSEcCtD
Apomorphine—Mental disorder—Doxorubicin—hematologic cancer	0.000211	0.00032	CcSEcCtD
Apomorphine—Vomiting—Etoposide—hematologic cancer	0.00021	0.000318	CcSEcCtD
Apomorphine—ADRA2C—lymph node—hematologic cancer	0.000207	0.0193	CbGeAlD
Apomorphine—Headache—Etoposide—hematologic cancer	0.000207	0.000314	CcSEcCtD
Apomorphine—Arthralgia—Methotrexate—hematologic cancer	0.000206	0.000313	CcSEcCtD
Apomorphine—Chest pain—Methotrexate—hematologic cancer	0.000206	0.000313	CcSEcCtD
Apomorphine—HTR2A—lung—hematologic cancer	0.000206	0.0192	CbGeAlD
Apomorphine—Fatigue—Prednisone—hematologic cancer	0.000204	0.000309	CcSEcCtD
Apomorphine—Headache—Prednisolone—hematologic cancer	0.000204	0.000309	CcSEcCtD
Apomorphine—Syncope—Epirubicin—hematologic cancer	0.000203	0.000308	CcSEcCtD
Apomorphine—Back pain—Doxorubicin—hematologic cancer	0.000203	0.000308	CcSEcCtD
Apomorphine—Constipation—Prednisone—hematologic cancer	0.000202	0.000307	CcSEcCtD
Apomorphine—Confusional state—Methotrexate—hematologic cancer	0.000199	0.000302	CcSEcCtD
Apomorphine—Loss of consciousness—Epirubicin—hematologic cancer	0.000199	0.000302	CcSEcCtD
Apomorphine—Dizziness—Triamcinolone—hematologic cancer	0.000198	0.0003	CcSEcCtD
Apomorphine—Nausea—Etoposide—hematologic cancer	0.000196	0.000297	CcSEcCtD
Apomorphine—Feeling abnormal—Prednisone—hematologic cancer	0.000195	0.000296	CcSEcCtD
Apomorphine—Asthenia—Betamethasone—hematologic cancer	0.000195	0.000296	CcSEcCtD
Apomorphine—Asthenia—Dexamethasone—hematologic cancer	0.000195	0.000296	CcSEcCtD
Apomorphine—HTR2A—testis—hematologic cancer	0.000194	0.0181	CbGeAlD
Apomorphine—Nausea—Prednisolone—hematologic cancer	0.000193	0.000293	CcSEcCtD
Apomorphine—Arthralgia—Epirubicin—hematologic cancer	0.000193	0.000293	CcSEcCtD
Apomorphine—Chest pain—Epirubicin—hematologic cancer	0.000193	0.000293	CcSEcCtD
Apomorphine—Anxiety—Epirubicin—hematologic cancer	0.000192	0.000292	CcSEcCtD
Apomorphine—Pruritus—Dexamethasone—hematologic cancer	0.000192	0.000291	CcSEcCtD
Apomorphine—Pruritus—Betamethasone—hematologic cancer	0.000192	0.000291	CcSEcCtD
Apomorphine—Hyperhidrosis—Methotrexate—hematologic cancer	0.000191	0.00029	CcSEcCtD
Apomorphine—Vomiting—Triamcinolone—hematologic cancer	0.00019	0.000289	CcSEcCtD
Apomorphine—Syncope—Doxorubicin—hematologic cancer	0.000188	0.000285	CcSEcCtD
Apomorphine—Headache—Triamcinolone—hematologic cancer	0.000187	0.000284	CcSEcCtD
Apomorphine—Confusional state—Epirubicin—hematologic cancer	0.000187	0.000283	CcSEcCtD
Apomorphine—Diarrhoea—Betamethasone—hematologic cancer	0.000186	0.000282	CcSEcCtD
Apomorphine—Diarrhoea—Dexamethasone—hematologic cancer	0.000186	0.000282	CcSEcCtD
Apomorphine—Oedema—Epirubicin—hematologic cancer	0.000185	0.000281	CcSEcCtD
Apomorphine—Hypotension—Methotrexate—hematologic cancer	0.000185	0.00028	CcSEcCtD
Apomorphine—Loss of consciousness—Doxorubicin—hematologic cancer	0.000184	0.00028	CcSEcCtD
Apomorphine—Shock—Epirubicin—hematologic cancer	0.000182	0.000276	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	0.00018	0.000273	CcSEcCtD
Apomorphine—Dizziness—Betamethasone—hematologic cancer	0.00018	0.000272	CcSEcCtD
Apomorphine—Dizziness—Dexamethasone—hematologic cancer	0.00018	0.000272	CcSEcCtD
Apomorphine—Hyperhidrosis—Epirubicin—hematologic cancer	0.000179	0.000271	CcSEcCtD
Apomorphine—Insomnia—Methotrexate—hematologic cancer	0.000179	0.000271	CcSEcCtD
Apomorphine—Arthralgia—Doxorubicin—hematologic cancer	0.000179	0.000271	CcSEcCtD
Apomorphine—Chest pain—Doxorubicin—hematologic cancer	0.000179	0.000271	CcSEcCtD
Apomorphine—Anxiety—Doxorubicin—hematologic cancer	0.000178	0.00027	CcSEcCtD
Apomorphine—Nausea—Triamcinolone—hematologic cancer	0.000178	0.00027	CcSEcCtD
Apomorphine—Dyspnoea—Methotrexate—hematologic cancer	0.000176	0.000267	CcSEcCtD
Apomorphine—Somnolence—Methotrexate—hematologic cancer	0.000176	0.000267	CcSEcCtD
Apomorphine—Hypotension—Epirubicin—hematologic cancer	0.000173	0.000262	CcSEcCtD
Apomorphine—Vomiting—Betamethasone—hematologic cancer	0.000173	0.000262	CcSEcCtD
Apomorphine—Vomiting—Dexamethasone—hematologic cancer	0.000173	0.000262	CcSEcCtD
Apomorphine—Confusional state—Doxorubicin—hematologic cancer	0.000173	0.000262	CcSEcCtD
Apomorphine—Oedema—Doxorubicin—hematologic cancer	0.000171	0.00026	CcSEcCtD
Apomorphine—Fatigue—Methotrexate—hematologic cancer	0.00017	0.000259	CcSEcCtD
Apomorphine—Headache—Dexamethasone—hematologic cancer	0.00017	0.000258	CcSEcCtD
Apomorphine—Headache—Betamethasone—hematologic cancer	0.00017	0.000258	CcSEcCtD
Apomorphine—Asthenia—Prednisone—hematologic cancer	0.00017	0.000257	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	0.000169	0.000256	CcSEcCtD
Apomorphine—Shock—Doxorubicin—hematologic cancer	0.000168	0.000255	CcSEcCtD
Apomorphine—Pruritus—Prednisone—hematologic cancer	0.000167	0.000254	CcSEcCtD
Apomorphine—Insomnia—Epirubicin—hematologic cancer	0.000167	0.000254	CcSEcCtD
Apomorphine—ADRA2A—lymph node—hematologic cancer	0.000165	0.0154	CbGeAlD
Apomorphine—Hyperhidrosis—Doxorubicin—hematologic cancer	0.000165	0.000251	CcSEcCtD
Apomorphine—Dyspnoea—Epirubicin—hematologic cancer	0.000165	0.00025	CcSEcCtD
Apomorphine—Somnolence—Epirubicin—hematologic cancer	0.000164	0.000249	CcSEcCtD
Apomorphine—Feeling abnormal—Methotrexate—hematologic cancer	0.000163	0.000247	CcSEcCtD
Apomorphine—Diarrhoea—Prednisone—hematologic cancer	0.000162	0.000245	CcSEcCtD
Apomorphine—Nausea—Dexamethasone—hematologic cancer	0.000161	0.000245	CcSEcCtD
Apomorphine—Nausea—Betamethasone—hematologic cancer	0.000161	0.000245	CcSEcCtD
Apomorphine—Hypotension—Doxorubicin—hematologic cancer	0.00016	0.000243	CcSEcCtD
Apomorphine—Fatigue—Epirubicin—hematologic cancer	0.000159	0.000242	CcSEcCtD
Apomorphine—Constipation—Epirubicin—hematologic cancer	0.000158	0.00024	CcSEcCtD
Apomorphine—Dizziness—Prednisone—hematologic cancer	0.000156	0.000237	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	0.000156	0.000237	CcSEcCtD
Apomorphine—Insomnia—Doxorubicin—hematologic cancer	0.000155	0.000235	CcSEcCtD
Apomorphine—Dyspnoea—Doxorubicin—hematologic cancer	0.000153	0.000231	CcSEcCtD
Apomorphine—Feeling abnormal—Epirubicin—hematologic cancer	0.000152	0.000231	CcSEcCtD
Apomorphine—Somnolence—Doxorubicin—hematologic cancer	0.000152	0.000231	CcSEcCtD
Apomorphine—Vomiting—Prednisone—hematologic cancer	0.00015	0.000228	CcSEcCtD
Apomorphine—Headache—Prednisone—hematologic cancer	0.000148	0.000225	CcSEcCtD
Apomorphine—Fatigue—Doxorubicin—hematologic cancer	0.000148	0.000224	CcSEcCtD
Apomorphine—Constipation—Doxorubicin—hematologic cancer	0.000146	0.000222	CcSEcCtD
Apomorphine—Asthenia—Methotrexate—hematologic cancer	0.000142	0.000215	CcSEcCtD
Apomorphine—Feeling abnormal—Doxorubicin—hematologic cancer	0.000141	0.000214	CcSEcCtD
Apomorphine—Nausea—Prednisone—hematologic cancer	0.00014	0.000213	CcSEcCtD
Apomorphine—Pruritus—Methotrexate—hematologic cancer	0.00014	0.000212	CcSEcCtD
Apomorphine—Diarrhoea—Methotrexate—hematologic cancer	0.000135	0.000205	CcSEcCtD
Apomorphine—Asthenia—Epirubicin—hematologic cancer	0.000133	0.000201	CcSEcCtD
Apomorphine—Pruritus—Epirubicin—hematologic cancer	0.000131	0.000199	CcSEcCtD
Apomorphine—Dizziness—Methotrexate—hematologic cancer	0.000131	0.000198	CcSEcCtD
Apomorphine—Diarrhoea—Epirubicin—hematologic cancer	0.000127	0.000192	CcSEcCtD
Apomorphine—Vomiting—Methotrexate—hematologic cancer	0.000126	0.000191	CcSEcCtD
Apomorphine—Headache—Methotrexate—hematologic cancer	0.000124	0.000188	CcSEcCtD
Apomorphine—Asthenia—Doxorubicin—hematologic cancer	0.000123	0.000186	CcSEcCtD
Apomorphine—Dizziness—Epirubicin—hematologic cancer	0.000122	0.000186	CcSEcCtD
Apomorphine—Pruritus—Doxorubicin—hematologic cancer	0.000121	0.000184	CcSEcCtD
Apomorphine—Vomiting—Epirubicin—hematologic cancer	0.000118	0.000178	CcSEcCtD
Apomorphine—Nausea—Methotrexate—hematologic cancer	0.000117	0.000178	CcSEcCtD
Apomorphine—Diarrhoea—Doxorubicin—hematologic cancer	0.000117	0.000178	CcSEcCtD
Apomorphine—Headache—Epirubicin—hematologic cancer	0.000116	0.000176	CcSEcCtD
Apomorphine—Dizziness—Doxorubicin—hematologic cancer	0.000113	0.000172	CcSEcCtD
Apomorphine—Nausea—Epirubicin—hematologic cancer	0.00011	0.000167	CcSEcCtD
Apomorphine—Vomiting—Doxorubicin—hematologic cancer	0.000109	0.000165	CcSEcCtD
Apomorphine—Headache—Doxorubicin—hematologic cancer	0.000107	0.000163	CcSEcCtD
Apomorphine—Nausea—Doxorubicin—hematologic cancer	0.000102	0.000154	CcSEcCtD
Apomorphine—DRD3—Signaling Pathways—STAT3—hematologic cancer	8.36e-06	2.53e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	8.36e-06	2.53e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MYC—hematologic cancer	8.35e-06	2.53e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—NRAS—hematologic cancer	8.34e-06	2.53e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	8.34e-06	2.53e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	8.34e-06	2.53e-05	CbGpPWpGaD
Apomorphine—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	8.34e-06	2.53e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	8.33e-06	2.52e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	8.32e-06	2.52e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	8.28e-06	2.51e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MTOR—hematologic cancer	8.28e-06	2.51e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	8.26e-06	2.5e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	8.26e-06	2.5e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL2—hematologic cancer	8.25e-06	2.5e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	8.23e-06	2.49e-05	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—AKT1—hematologic cancer	8.22e-06	2.49e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—KRAS—hematologic cancer	8.21e-06	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	8.21e-06	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	8.17e-06	2.47e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	8.17e-06	2.47e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—JUN—hematologic cancer	8.15e-06	2.47e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PTEN—hematologic cancer	8.15e-06	2.47e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	8.15e-06	2.47e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	8.15e-06	2.47e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	8.14e-06	2.47e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	8.12e-06	2.46e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PTEN—hematologic cancer	8.11e-06	2.46e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MAPK3—hematologic cancer	8.1e-06	2.45e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—KRAS—hematologic cancer	8.08e-06	2.45e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	8.05e-06	2.44e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	8.04e-06	2.44e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	8.03e-06	2.43e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	8.02e-06	2.43e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MAPK3—hematologic cancer	7.99e-06	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	7.99e-06	2.42e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	7.97e-06	2.41e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	7.95e-06	2.41e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	7.93e-06	2.4e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	7.91e-06	2.4e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—HRAS—hematologic cancer	7.9e-06	2.39e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	7.9e-06	2.39e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	7.88e-06	2.39e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MYC—hematologic cancer	7.87e-06	2.39e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TGFB1—hematologic cancer	7.86e-06	2.38e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	7.83e-06	2.37e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	7.8e-06	2.36e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	7.78e-06	2.36e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	7.78e-06	2.36e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—EP300—hematologic cancer	7.77e-06	2.35e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MYC—hematologic cancer	7.77e-06	2.35e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	7.77e-06	2.35e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MYC—hematologic cancer	7.77e-06	2.35e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	7.76e-06	2.35e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	7.75e-06	2.35e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TGFB1—hematologic cancer	7.75e-06	2.35e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—EP300—hematologic cancer	7.73e-06	2.34e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—KRAS—hematologic cancer	7.72e-06	2.34e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	7.71e-06	2.34e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	7.71e-06	2.33e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	7.69e-06	2.33e-05	CbGpPWpGaD
Apomorphine—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	7.69e-06	2.33e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTEN—hematologic cancer	7.66e-06	2.32e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	7.65e-06	2.32e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	7.65e-06	2.32e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	7.62e-06	2.31e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	7.62e-06	2.31e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CASP3—hematologic cancer	7.61e-06	2.31e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL2—hematologic cancer	7.6e-06	2.3e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	7.59e-06	2.3e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	7.57e-06	2.29e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—IL6—hematologic cancer	7.57e-06	2.29e-05	CbGpPWpGaD
Apomorphine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	7.56e-06	2.29e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—SRC—hematologic cancer	7.56e-06	2.29e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	7.55e-06	2.29e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	7.55e-06	2.29e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	7.53e-06	2.28e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—EP300—hematologic cancer	7.52e-06	2.28e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—SRC—hematologic cancer	7.52e-06	2.28e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	7.49e-06	2.27e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL2—hematologic cancer	7.48e-06	2.27e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TP53—hematologic cancer	7.46e-06	2.26e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	7.44e-06	2.25e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	7.43e-06	2.25e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CCND1—hematologic cancer	7.41e-06	2.25e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	7.41e-06	2.25e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	7.41e-06	2.25e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	7.4e-06	2.24e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—JUN—hematologic cancer	7.4e-06	2.24e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	7.36e-06	2.23e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	7.32e-06	2.22e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—SRC—hematologic cancer	7.31e-06	2.21e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—EP300—hematologic cancer	7.3e-06	2.21e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TP53—hematologic cancer	7.3e-06	2.21e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	7.29e-06	2.21e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—STAT3—hematologic cancer	7.29e-06	2.21e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—JUN—hematologic cancer	7.28e-06	2.2e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—KRAS—hematologic cancer	7.28e-06	2.2e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NRAS—hematologic cancer	7.27e-06	2.2e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	7.25e-06	2.2e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	7.23e-06	2.19e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	7.21e-06	2.18e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	7.2e-06	2.18e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TP53—hematologic cancer	7.18e-06	2.18e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—KRAS—hematologic cancer	7.18e-06	2.17e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	7.18e-06	2.17e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	7.17e-06	2.17e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PTEN—hematologic cancer	7.15e-06	2.17e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—HRAS—hematologic cancer	7.13e-06	2.16e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	7.12e-06	2.16e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	7.09e-06	2.15e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	7.08e-06	2.14e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	7.06e-06	2.14e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	7.05e-06	2.14e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	7.04e-06	2.13e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	7.03e-06	2.13e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	7.01e-06	2.12e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	7.01e-06	2.12e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MAPK8—hematologic cancer	7e-06	2.12e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	7e-06	2.12e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—HRAS—hematologic cancer	6.98e-06	2.11e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—AKT1—hematologic cancer	6.98e-06	2.11e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	6.96e-06	2.11e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	6.96e-06	2.11e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	6.94e-06	2.1e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	6.93e-06	2.1e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	6.92e-06	2.1e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	6.89e-06	2.09e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	6.88e-06	2.08e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—HRAS—hematologic cancer	6.87e-06	2.08e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	6.87e-06	2.08e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TP53—hematologic cancer	6.86e-06	2.08e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—IL6—hematologic cancer	6.82e-06	2.07e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—EP300—hematologic cancer	6.82e-06	2.07e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	6.82e-06	2.06e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	6.81e-06	2.06e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	6.77e-06	2.05e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MYC—hematologic cancer	6.77e-06	2.05e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	6.76e-06	2.05e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	6.74e-06	2.04e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MYC—hematologic cancer	6.74e-06	2.04e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	6.72e-06	2.04e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—EP300—hematologic cancer	6.71e-06	2.03e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	6.68e-06	2.02e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—IL6—hematologic cancer	6.68e-06	2.02e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	6.65e-06	2.02e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	6.64e-06	2.01e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—SRC—hematologic cancer	6.63e-06	2.01e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	6.63e-06	2.01e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	6.62e-06	2.01e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	6.6e-06	2e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	6.6e-06	2e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—IL6—hematologic cancer	6.58e-06	1.99e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—HRAS—hematologic cancer	6.56e-06	1.99e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	6.55e-06	1.98e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	6.54e-06	1.98e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—SRC—hematologic cancer	6.53e-06	1.98e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	6.48e-06	1.96e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TP53—hematologic cancer	6.47e-06	1.96e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—VEGFA—hematologic cancer	6.46e-06	1.96e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	6.45e-06	1.95e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	6.43e-06	1.95e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	6.42e-06	1.94e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	6.4e-06	1.94e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—STAT3—hematologic cancer	6.4e-06	1.94e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NRAS—hematologic cancer	6.38e-06	1.93e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TP53—hematologic cancer	6.38e-06	1.93e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TP53—hematologic cancer	6.38e-06	1.93e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	6.36e-06	1.93e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	6.3e-06	1.91e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—AKT1—hematologic cancer	6.3e-06	1.91e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	6.28e-06	1.9e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—IL6—hematologic cancer	6.28e-06	1.9e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	6.27e-06	1.9e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—KRAS—hematologic cancer	6.26e-06	1.9e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	6.25e-06	1.89e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	6.22e-06	1.89e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—HRAS—hematologic cancer	6.18e-06	1.87e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—AKT1—hematologic cancer	6.16e-06	1.87e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MAPK3—hematologic cancer	6.11e-06	1.85e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	6.11e-06	1.85e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—HRAS—hematologic cancer	6.1e-06	1.85e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	6.1e-06	1.85e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—AKT1—hematologic cancer	6.07e-06	1.84e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	6.05e-06	1.83e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	6.01e-06	1.82e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	5.96e-06	1.8e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	5.95e-06	1.8e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MYC—hematologic cancer	5.95e-06	1.8e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	5.94e-06	1.8e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TGFB1—hematologic cancer	5.93e-06	1.8e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—IL6—hematologic cancer	5.92e-06	1.79e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MYC—hematologic cancer	5.85e-06	1.77e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—IL6—hematologic cancer	5.84e-06	1.77e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—IL6—hematologic cancer	5.84e-06	1.77e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	5.84e-06	1.77e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—AKT1—hematologic cancer	5.79e-06	1.75e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	5.78e-06	1.75e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	5.76e-06	1.75e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	5.75e-06	1.74e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	5.73e-06	1.73e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	5.72e-06	1.73e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	5.71e-06	1.73e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	5.56e-06	1.68e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TP53—hematologic cancer	5.56e-06	1.68e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TP53—hematologic cancer	5.53e-06	1.68e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	5.51e-06	1.67e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—KRAS—hematologic cancer	5.49e-06	1.66e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	5.47e-06	1.66e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	5.47e-06	1.66e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—AKT1—hematologic cancer	5.46e-06	1.65e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—AKT1—hematologic cancer	5.43e-06	1.65e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	5.41e-06	1.64e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	5.4e-06	1.64e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—AKT1—hematologic cancer	5.39e-06	1.63e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	5.39e-06	1.63e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	5.38e-06	1.63e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	5.32e-06	1.61e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—HRAS—hematologic cancer	5.32e-06	1.61e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	5.31e-06	1.61e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	5.3e-06	1.6e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	5.29e-06	1.6e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	5.27e-06	1.6e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	5.15e-06	1.56e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—IL6—hematologic cancer	5.09e-06	1.54e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	5.06e-06	1.53e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—IL6—hematologic cancer	5.06e-06	1.53e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	5.05e-06	1.53e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	4.97e-06	1.5e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	4.93e-06	1.49e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	4.92e-06	1.49e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TP53—hematologic cancer	4.88e-06	1.48e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	4.86e-06	1.47e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	4.85e-06	1.47e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TP53—hematologic cancer	4.8e-06	1.46e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—AKT1—hematologic cancer	4.7e-06	1.42e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	4.67e-06	1.42e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—HRAS—hematologic cancer	4.67e-06	1.41e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	4.59e-06	1.39e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	4.54e-06	1.38e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	4.52e-06	1.37e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	4.47e-06	1.35e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL6—hematologic cancer	4.47e-06	1.35e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—AKT1—hematologic cancer	4.41e-06	1.34e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL6—hematologic cancer	4.4e-06	1.33e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	4.37e-06	1.32e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	4.18e-06	1.27e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—AKT1—hematologic cancer	4.12e-06	1.25e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	4.06e-06	1.23e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	4e-06	1.21e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	3.69e-06	1.12e-05	CbGpPWpGaD
